Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.
Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 microg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.
Ginsburg
Amy Sarah
AS
Center for Tuberculosis Research, 1503 E. Jefferson Street, Baltimore, MD 21231-1001, USA.
Sun
Ronggai
R
Calamita
Heather
H
Scott
Cherise P
CP
Bishai
William R
WR
Grosset
Jacques H
JH
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D027081:DNA Gyrase / Q000235:genetics; D017931:DNA Primers; D004032:Diet; D024881:Drug Resistance, Bacterial; D004435:Eating; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D017931:DNA Primers; D024841:Fluoroquinolones; D011804:Quinolines; D027081:DNA Gyrase; D000077266:Moxifloxacin